Latest News - Earnings & Financials

Monday, February 19, 2018 | Earnings & Financials, Novartis

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The generic drug business has faced some struggles of recent amid that decline Swiss pharmaceutical company Novartis AG (NVS - Get Report) is reportedly gearing up to launch a sale process for its U.S…

Read the full story

Wednesday, February 07, 2018 | Earnings & Financials, Allergan

Allergan's Profit Beats; Migraine Drug Succeeds in Key Study

Allergan on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study. The key data could ease some …

Read the full story

Monday, February 05, 2018 | Earnings & Financials, Second Sight Medical Products

Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant

Second Sight Medical Products provided a company update on the commercialization of its products, including the first-in-human implant of thee Orion Cortical Visual Prosthesis System. “We are…

Read the full story

Friday, February 02, 2018 | Earnings & Financials, Allergan

Settling a Post-Buyout Hangover, Allergan Gives Teva a $700M Remedy

Teva and Allergan have put aside their differences -- and the result is an influx of cash that Teva badly needs, according to a report in FiercePharma. Wednesday, the former deal partners inked an …

Read the full story

Friday, February 02, 2018 | Earnings & Financials

Eyenovia Announces Closing of $27.3 Million Initial Public Offering

Eyenovia announced the closing of its initial public offering of 2,730,000 shares of its common stock. Eyenovia received $27.3 million in gross proceeds from the offering, before underwriting discount…

Read the full story

Wednesday, January 31, 2018 | Earnings & Financials, Glaucoma

InFocus Capital Partners Completes Series A Investment in Qura

InFocus Capital Partners, an investment firm specializing in the identification and commercialization of ophthalmic health care innovations, has provided a Series A round of funding for Qura Inc. to a…

Read the full story

Tuesday, January 30, 2018 | Earnings & Financials

Vital Art and Science Looks to Sell myVisionTrack Technology

Vital Art and Science announced that it has retained Telos Capital Advisors as its exclusive investment banking advisor to represent the company in the sale of its myVisionTrack technology, also known…

Read the full story

Wednesday, January 24, 2018 | Earnings & Financials, Novartis

Novartis Poised for Growth as CEO Hands Baton to U.S. Newcomer

Novartis expects to return to operating profit growth this year, with new Chief Executive Vas Narasimhan inheriting the Swiss drugmaker just as revenue from its latest medicines accelerates and the im…

Read the full story

Tuesday, January 16, 2018 | Earnings & Financials, Allergan

Ackman looks to persuade judge $290M Allergan settlement is fair

Bill Ackman is going to try and hold onto a little cash on Tuesday. Lawyers for the embattled hedgie will appear before a federal judge in Los Angeles in an attempt to persuade him the $290 million se…

Read the full story

Tuesday, January 09, 2018 | Earnings & Financials, Shire

Shire to Operate as Two Business Units Focused on Neuroscience, Rare Diseases

Shire said that following the first stage of its strategic review, it will separate its operations into two divisions, namely neuroscience and rare diseases. CEO Flemming Ornskov stated "our new …

Read the full story

Monday, January 08, 2018 | Earnings & Financials, Alimera Sciences

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences announced that it has entered into a $40 million term loan agreement with Solar Capital Ltd. Alimera will use the proceeds of this funding to pay off an existing $35 million term…

Read the full story

Friday, January 05, 2018 | Earnings & Financials, Psivida

pSivida Granted Waiver by the FDA for New Drug Application Filing Fee

pSivida Corp. announced that the FDA granted its request for a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of approximately $2.4 million for its new drug application (NDA) …

Read the full story

Thursday, January 04, 2018 | Earnings & Financials, Retina

Oculis Raises $20.3 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases

Oculis announced it has successfully closed a Series B financing round of CHF 20 million ($20.3 million). The funds will be used to advance the clinical development of the company’s lead program…

Read the full story

Thursday, January 04, 2018 | Earnings & Financials, Allergan

Allergan Plans to Eliminate More Than 1,000 Jobs as Part of Restructuring Initiative

Allergan on Wednesday unveiled in a regulatory filing that it plans to cut its labor force by more than 1,000 positions as part of a cost-cutting initiative. The drugmaker noted that &q…

Read the full story

Tuesday, December 26, 2017 | Corporate Lawsuits, Earnings & Financials, Ocular Therapeutix

Ocular Therapeutix Provides Legal Update

Ocular Therapeutix provided an update on legal matters related to the company’s manufacture of its product candidate, Dextenza (dexamethasone insert) 0.4mg. As the company previously disclose…

Read the full story
Load More